NOURIANZ
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $2,174 | 6 | 2 |
| 2022 | $3.1M | 4,745 | 1,948 |
| 2021 | $1.2M | 7,394 | 2,579 |
| 2020 | $979,847 | 5,181 | 1,864 |
| 2019 | $430,395 | 1,682 | 1,022 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.0M | 967 | 34.6% |
| Unspecified | $1.7M | 10 | 30.7% |
| Consulting Fee | $1.1M | 370 | 19.3% |
| Food and Beverage | $391,723 | 16,772 | 6.9% |
| Travel and Lodging | $220,620 | 785 | 3.9% |
| Honoraria | $194,863 | 76 | 3.4% |
| Education | $56,809 | 25 | 1.0% |
| Grant | $12,000 | 2 | 0.2% |
| Space rental or facility fees (teaching hospital only) | $800.00 | 1 | 0.0% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| An open label study to evaluate the safety and efficacy of combination extracorporeal photopheresis (ECP) and mogamulizumab in erythrodermic CTCL | Kyowa Kirin, Inc. | $1.2M | 0 |
| Istradefylline effect on Parkinsons Disease Tremor, Motor symptoms and Non-motor symptoms | Kyowa Kirin, Inc. | $281,204 | 0 |
| Istradefylline for Parkinson disease dementia | Kyowa Kirin, Inc. | $251,370 | 0 |
| A Phase 2, Double-blind, Placebo-controlled, Randomized, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of 40mgDay KW-6002 Istradefylline as Monotherapy in Subjects With Parkinsons Disease | Kyowa Kirin Pharmaceutical Development, Inc | $9,761 | 0 |
| Adenosine A2A Blockade With KW-6002 in Parkinsons Disease | Kyowa Kirin Pharmaceutical Development, Inc | $3,225 | 2 |
| Effectiveness of Istradefylline on Motor Functions in Patients with Parkinson's Disease | Kyowa Kirin, Inc. | $2,128 | 0 |
Top Doctors Receiving Payments for NOURIANZ
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Phoenix, AZ | $1.9M | 68 |
| , MD | Neurology | Boca Raton, FL | $225,751 | 158 |
| , M.D | Neurology | Loma Linda, CA | $199,051 | 136 |
| , MD | Neurology | Oklahoma City, OK | $181,488 | 138 |
| , M.D | Neurology | Alexandria, VA | $155,327 | 112 |
| , MD | Neurology | Augusta, GA | $138,878 | 108 |
| , MD | Neurology | Houston, TX | $109,991 | 81 |
| , MD | Specialist | Kirkland, WA | $106,217 | 80 |
| , M.D | Neurology | Herrin, IL | $102,513 | 94 |
| , MD | Neurology | Tampa, FL | $99,587 | 64 |
| , M.D | Neurology | Commack, NY | $96,930 | 74 |
| , D.O, | Neurology | Washington, DC | $95,691 | 88 |
| , M.D | Neurology | Dallas, TX | $93,639 | 95 |
| , M.D | Neurology | Hershey, PA | $86,685 | 57 |
| , M.D., J.D | Neurology | Philadelphia, PA | $85,174 | 56 |
| , M.D | Neurology | Los Angeles, CA | $78,465 | 55 |
| , M.D | Neurology | Toledo, OH | $74,508 | 45 |
| , MD | Specialist | Port Charlotte, FL | $65,595 | 83 |
| , MD, PH.D | Neurology | New York, NY | $63,788 | 76 |
| , DO | Neurology | Philadelphia, PA | $63,460 | 50 |
| , M.D | Neurology | West Bloomfield, MI | $63,383 | 60 |
| , M.D | Neurology | Allentown, PA | $61,736 | 55 |
| , M.D | Neurology | Washington, DC | $60,959 | 73 |
| , M.D | Neurology | Houston, TX | $59,536 | 58 |
| , MD | Neurology | Phoenix, AZ | $58,976 | 79 |
Manufacturing Companies
- Kyowa Kirin, Inc. $5.7M
- Kyowa Kirin Pharmaceutical Development, Inc $12,986
- Kyowa Kirin Services Ltd $6,000
Product Information
- Type Drug
- Total Payments $5.7M
- Total Doctors 4,480
- Transactions 19,008
About NOURIANZ
NOURIANZ is a drug associated with $5.7M in payments to 4,480 healthcare providers, recorded across 19,008 transactions in the CMS Open Payments database. The primary manufacturer is Kyowa Kirin, Inc..
Payment data is available from 2019 to 2023. In 2023, $2,174 was paid across 6 transactions to 2 doctors.
The most common payment nature for NOURIANZ is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($2.0M, 34.6% of total).
NOURIANZ is associated with 6 research studies, including "An open label study to evaluate the safety and efficacy of combination extracorporeal photopheresis (ECP) and mogamulizumab in erythrodermic CTCL" ($1.2M).